<DOC>
	<DOCNO>NCT00101140</DOCNO>
	<brief_summary>RATIONALE : A peripheral stem cell transplant may able replace blood-forming cell destroy chemotherapy radiation therapy . Sometimes transplanted cell donor make immune response body 's normal cell . Giving total-body irradiation together fludarabine , thiotepa , antithymocyte globulin transplant may stop happen . PURPOSE : This phase II trial study well donor stem cell transplant work treat patient acute myeloid leukemia remission .</brief_summary>
	<brief_title>Donor Stem Cell Transplant Treating Patients With Acute Myeloid Leukemia Remission</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety antileukemia activity haploidentical allogeneic peripheral blood stem cell transplantation patient high-risk acute myeloid leukemia first remission . Secondary - Determine early treatment-related mortality ( day 100 ) patient treat regimen . - Determine incidence acute graft-versus-host disease patient treat regimen . - Determine incidence graft failure patient treat regimen . - Correlate mismatch expression natural killer cell inhibitory receptor CD158a CD158b engraftment disease recurrence patient treat regimen . OUTLINE : This multicenter study . Patients receive preparative regimen comprise total-body irradiation twice day –8 ; fludarabine IV 30 minute day –7 –3 ; thiotepa IV 2 hour twice day –7 ; antithymocyte globulin IV 4-6 hour day –5 –2 . Patients undergo haploidentical allogeneic peripheral blood stem cell transplantation day 0 . Patients follow day 100 , least monthly 2 year , periodically 3 year . PROJECTED ACCRUAL : A total 44 patient accrue study within 2.2 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Morphologically confirm acute myeloid leukemia 1 follow subtypes : Acute myeloblastic leukemia ( M0 , M1 , M2 ) Acute myelomonocytic leukemia ( M4 ) Acute monocytic leukemia ( M5 ) Acute erythroleukemia ( M6 ) Acute megakaryocytic leukemia ( M7 ) Must 1 follow karyotypic abnormality time diagnosis : Complex cytogenetic abnormality ( ≥ 3 cytogenetic clone ) Abnormalities chromosome 5 [ 5 del ( 5q ) ] Abnormalities long ( q ) arm chromosome 3 , 9 , 11 , 20 , 21 Abnormalities short ( p ) arm chromosome 17 , monosomy 7 , ( 9 ; 22 ) , ( 6 ; 9 ) ( 8 ) In morphologic first complete remission* , evidence follow ≥ 4 week study entry : Absolute neutrophil count &gt; 1,000/mm^3 Platelet count &gt; 100,000/mm^3 Leukemic blast present peripheral blood Cellularity bone marrow biopsy &gt; 20 % maturation cell line Less 5 % blast bone marrow biopsy No extramedullary leukemia , CNS soft tissue involvement NOTE : *Reduced hemoglobin concentration hematocrit bear remission status Haploidentical ( 3/6 4/6 antigen match [ A , B , DR ] ) family donor available PATIENT CHARACTERISTICS : Age 18 59 Performance status ECOG 02 Life expectancy Not specify Hematopoietic See Disease Characteristics Hepatic Bilirubin ≤ 2.0 mg/dL AST &lt; 2 time upper limit normal Renal Creatinine ≤ 1.5 mg/dL Cardiovascular Ejection fraction &gt; 40 % MUGA echocardiogram None follow within past 3 month : Myocardial infarction Significant congestive heart failure Significant cardiac arrhythmia Pulmonary FEV_1 DLCO &gt; 50 % predict Immunologic HIV negative No active unresolved infection No evidence invasive fungal infection ( e.g. , positive blood deep tissue culture stain ) Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No organ damage No medical problem would preclude study participation No currently active tumor would likely interfere study treatment would likely compromise patient ’ morbidity mortality PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent routine use filgrastim ( GCSF ) sargramostim ( GMCSF ) accelerate hematopoietic recovery posttransplantation Chemotherapy More 4 week since prior chemotherapy Endocrine therapy Not specify Radiotherapy More 4 week since prior radiotherapy Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>July 2006</verification_date>
	<keyword>adult erythroleukemia ( M6a )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
</DOC>